HHS said the tests, authorized Aug. 26, may be deployed to schools and other “special needs” populations.
Healthcare providers using Abbott’s test will swab a patient’s nose, transfer the sample to a test card and wait 15 minutes to read the results directly from the card.
“This means people will know if they have the virus in almost real time. Due to its simpler design and the large number of tests the company anticipates making in the coming months, this new antigen test is an important advancement in our fight against the pandemic,” Jeff Shuren, MD, director of the FDA’s Center for Devices and Radiological Health, said in a news release.
Abbott said it plans to make up to 50 million tests per month starting in October.
Read HHS full news release here.
More articles on supply chain:
UVA Health System designs swab to boost COVID-19 testing in Virginia
Medical device recalls rise 31% in Q2
FEMA may no longer reimburse states for COVID-19 supplies: report
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
